Entering text into the input field will update the search result below

Selecta Biosciences (SELB) Presents On New SEL-212 Phase 2 Data

SA Transcripts profile picture
SA Transcripts

The following slide deck was published by Selecta Biosciences in conjunction with this event.

New SEL-212 Phase 2 Data

This article was written by

SA Transcripts profile picture
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Recommended For You

Comments (2)

This data looks very strong
These data look strong only up to three months (12 weeks shown in Slide 5); however, by month six (see slides 6 and 8) the patients who had not failed earlier are loosing uric acid control (three out of five patients in slide 6 and three out of three patients in slide 8). This indicates that durable tolerance to pegsiticase was not induced by any of the tested dosage regimens.

Strong data would be expected to include evidence for resolution of gouty tophi, as has been reported for pegloticase (without immunosuppression).
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.